An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Trial Profile

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Alcoholic hepatitis
  • Focus Adverse reactions
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 01 Mar 2018 Status changed from not yet recruiting to recruiting according to a DURECT Corporation media release.
    • 01 Mar 2018 According to a DURECT Corporation media release, data from this trial are expected in 2018.
    • 15 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top